Novo Nordisk

Hims & Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant. Check out the current price of HIMS...

Novo Nordisk A/S (NYSE:NVO) is seeking FDA approval for the pill version of its obesity drug, Wegovy. The company recently highlighted early data that shows safety and efficacy figures that are similar to its injectables. What Happened: On Wednesday, during Novo’s first quarter earnings call...

Wall Street experienced a resurgence in risk appetite on Thursday as optimism grew around trade negotiations. President Donald Trump expressed confidence in reaching agreements with both the European Union and China. On Thursday, the Dow Jones Industrial Average fell 1.3% to close at 39,142.23....

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) received reaffirmed buy ratings from both H.C. Wainwright and Oppenheimer this week, with analysts citing the company's diversified pipeline as a key driver for future growth, despite a sharp stock decline after Novo Nordisk‘s (NYSE:NVO) mid...

Editor’s Note: This story has been updated to include a statement from a Novo Nordisk spokesperson. Sen. Bernie Sanders (I-Vt.) has once again criticized Novo Nordisk A/S (NYSE:NVO) for the high price of its diabetes drug, Ozempic, in the United States. What Happened: On Sunday, Sanders took...

Shares of Corbus Pharmaceuticals (NASDAQ:CRBP) experienced a severe drop on Friday, plummeting almost 60% from $52 to $21, as competitor Novo Nordisk (NYSE:NVO) published trial results for monlunabant, a cannabinoid receptor 1 (CB1) inverse agonist. Novo Nordisk shares also traded down roughly 5.5...

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO). What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug...

On Tuesday, U.S. stocks showed mixed results. The Dow Jones Industrial Average closed down by nearly 0.8%, finishing at 39,112.16. The S&P 500 rose by almost 0.4% to end the regular session at 5,469.30, while the Nasdaq climbed nearly 1.3% to close at 17,717.65. These are the top stocks that...

Novo Nordisk A/S (NYSE:NVO) is facing a significant challenge in China, where local pharmaceutical companies are developing generic versions of its key diabetes and obesity drugs. What Happened: As reported by Reuters on Sunday, at least 15 Chinese drugmakers are working on generic versions of Novo...

In a move to demystify the conversation around obesity and weight management medications, Oprah Winfrey has taken to the airwaves with a prime-time special that delves into the stigma associated with weight loss drugs like Ozempic and Wegovy. What Happened: Winfrey dedicated a prime-time special to...

The Centers for Medicare and Medicaid Services (CMS) is considering the inclusion of Novo Nordisk’s (NYSE:NVO) obesity drug Wegovy in its coverage for heart disease patients with obesity. What Happened: The CMS is reviewing the FDA's action to expand the use of Wegovy to reduce the risk of...

Ozempic maker Novo Nordisk (NYSE:NVO), a Danish pharmaceutical company, is set to launch its weight-loss drug, Wegovy, in Japan. This move is in response to the rising obesity rates in the country. What Happened: Despite Japan’s reputation for being health-conscious, the country has seen a...

CNBC host Jim Cramer advised investors to gear up for a potential market sell-off, asserting that they should be ready to make purchases if undervalued stocks dip. What Happened: Cramer, in his show “Mad Money,” dismissed the notion of sector bubbles and encouraged investors to be...

Novo Holdings, the major shareholder of Danish pharmaceutical company Novo Nordisk (NYSE:NVO), plans to ramp up its annual investments to $7 billion by 2030. What Happened: The investment firm, which manages the assets of the Novo Nordisk Foundation, intends to increase its annual investments from...

Maker of ‘miracle’ weight loss drugs Ozempic and Wegovy, Novo Nordisk A/S (NYSE:NVO) has announced the acquisition of three fill-finish sites from Novo Holdings A/S for $11 billion. The acquisition is part of a larger deal where Novo Holdings is set to acquire Catalent, Inc. (NYSE:CTLT...